Curaleaf Isn’t Just Selling Marijuana Anymore

美国大麻销售商 Curaleaf 推出 CBD 产品,预计2019年销售额可达4亿美元

2019-03-22 08:40:00 Barrons.com

本文共785个字,阅读需2分钟

As American cannabis seller Curaleaf Holdings reported a 43% sales rise from the September to December quarters, it announced that it’s jumping into the hemp field. Chief executive Joe Lusardi told Barron’s that the company’s Curaleaf Hemp products are already at retailers like CVS (CVS). Since Congress legalized hemp—a variety of cannabis with soothing ingredients like CBD, but not the intoxicating THC—Curaleaf and its peers are rushing out products they hope will become bigger sellers than marijuana, now that CBD can be sold anywhere. Curaleaf will promote its hemp products through a deal with Hearst Media. Curaleaf, bankrolled by Russian billionaires, trades on the Canadian Securities Exchange and the OTC Market in the U.S., because pot’s federal illegality here has deterred big exchanges from listing the stocks of American cannabis sellers. Hanging over the thinly-traded shares of the company and other Canada-listed U.S. sellers are piles of insider shares. On Wednesday, Curaleaf’s founders and key shareholders agreed to extend the initial offering lockup on the 81% of Curaleaf stock they own, to October 20, 2019. On Wednesday night’s news, Curaleaf’s over the counter stock, which trades under the ticker CURLF has gained 3.4% to $6.86, while its Canadian listed shares, which trade under the ticker CURA, have risen 7% to C$9.70 on light volume. The Wakefield, Mass.-based chain achieved $35 million in sales through dispensaries that it owns or manages in the December stretch, with a loss of $17 million, or 4 cents a share. Ignoring such costs as depreciation, acquisitions and stock compensation, Curaleaf’s cash flow was a negative $3.4 million in the quarter. Growth came from acquisitions and new store openings in states like Florida, the company said. Curaleaf now runs 43 dispensaries around the country. It reaffirmed its guidance that sales can reach $400 million in 2019, with free cash flow (including acquisition costs) of $100 million.
正如美国大麻销售商 Curaleaf Holdings 公布的9月至12月季度销售额增长43%一样,该公司宣布将进军大麻领域。首席执行官 Joe Lusardi 告诉 Barron's ,该公司的 Curaleaf Hemp 产品已经在 CVS ( CVS )等零售商销售。由于国会将大麻合法化——一种含有舒缓成分的大麻,如 CBD ,但不是令人陶醉的 THC —— Curaleaf 及其同行纷纷推出他们希望比大麻更畅销的产品,因为 CBD 可以在任何地方销售。Curaleaf 将通过与赫斯特媒体达成协议,推广其大麻产品。 在俄罗斯亿万富翁的资助下, Curaleaf 在加拿大证券交易所( Canadian Securities Exchange )和美国场外市场( OTC Market )进行交易,因为大麻的联邦非法性阻止了大型交易所将美国大麻卖家的股票上市。在加拿大上市的公司和其他在加拿大上市的美国卖家的股票交易不活跃,导致大量内幕交易。周三, Curaleaf 的创始人和主要股东同意将其持有的 Curaleaf 81%的股份的首次公开发行( IPO )锁定期延长至2019年10月20日。周三晚间的消息是, Curaleaf 的场外交易股票 CURLF 股价上涨3.4%,至6.86美元,加拿大上市股票 CURA 股价上涨7%,至9.70加元。 马萨诸塞州韦克菲尔德.这家总部位于美国的连锁药店去年12月通过药房实现了3500万美元的销售额,损失了1700万美元,即每股4美分。排除折旧、收购和股票补偿等成本, Curaleaf 本季度的现金流为负340万美元。 该公司表示,增长来自收购和在弗洛里达州等州开设新店。Curaleaf 现在在全国经营43家药房。该公司重申其指导意见,即2019年销售额可达4亿美元,自由现金流(包括收购成本)为1亿美元。

以上中文文本为机器翻译,存在不同程度偏差和错误;偶尔因源网页结构局限,内容无法一次完整呈现。请理解并参考原站原文阅读。

阅读原文